# A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2

> **NCT04721535** · PHASE3 · TERMINATED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 9 (actual)

## Conditions studied

- Covid19
- SARS-COV-2 Infection

## Interventions

- **DRUG:** DWJ1248
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04721535
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-07
- **Primary completion:** 2021-09-23
- **Final completion:** 2021-10-06
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Termination of study due to sponsor's internal decision
- **Last updated:** 2022-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04721535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04721535, "A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04721535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*